Health

FDA suggests limits on lead in cosmetics

(HealthDay)—The U.S. Food and Drug Administration has suggested setting a limit on how much lead can be in cosmetics ranging from lipstick and eye shadow to blush and shampoo.

Medications

FDA Oks first muscular dystrophy drug; awaits proof it works

Federal regulators on Monday granted tentative approval to the first drug for muscular dystrophy, following an intense public campaign from patients and doctors who pushed for the largely unproven medication.

Medical research

Study could herald new treatment for muscular dystrophy

New research has shown that the corticosteroid deflazacort is a safe and effective treatment for Duchenne muscular dystrophy. The findings, which appear this month in the journal Neurology, could pave the way for first U.S.-approved ...

Medications

Harms reporting in trials of orlistat

The reporting of trials of orlistat in the 1990s appears to have understated harms, both in the summarized results submitted to the European Medicines Agency for drug approval, and in the published papers, according to a ...

Medications

Lower-cost biotech drug gets thumbs up from FDA panel (Update)

The second-biggest selling drug in the world could get some cheaper competition in the U.S., after a federal panel endorsed an alternative version of the pricey medication used to treat rheumatoid arthritis and other inflammatory ...

Medications

FDA approves first pill to treat all forms of hepatitis C

Federal health officials on Tuesday approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus.

Medications

'Female libido' pill may not be worth it: researchers

(HealthDay)—The much-touted "female libido" pill seems to cause a host of serious side effects while failing to spark much additional passion in a woman's life, a new review suggests.

Oncology & Cancer

New study questions clinical trial data for kidney cancer drugs

When prescribing newly approved drugs, physicians rely on data from clinical trials to understand the benefits and risks of those drugs for patients. But a study published in the Journal of Oncology Practice showed that for ...

page 12 from 24